2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-162609
    ST-2560
    ST-2560 is a selective inhibitor of the NaV1.7 sodium channel with IC50 value of 39 nM. ST-2560 can be used to study pain behavior and cardiovascular models.
    ST-2560
  • HY-162613
    ASM-IN-2 2305789-66-4
    ASM-IN-2 (Compound 46) is a potent ASM inhibitor with an IC50 value of 0.87 μM, displaying good drug-like properties. ASM-IN-2 involves in multiple antidepressant mechanisms of actionin, which are associated with a decline of ceramide. It demostrates remarkable antidepressant effects in the CUMS-induced mouse, which is promising for research in the field of antidepressant drugs.
    ASM-IN-2
  • HY-162636
    5HT6-ligand-2
    5HT6-ligand-2 (compound 15) is a potent 5-HT6 inhibitor with Ki values of 3.4, 15 nM for 5-HT6, SERT, respectively. 5HT6-ligand-2 shows neuroprotection. 5HT6-ligand-2 has the potential for the research of dementia.
    5HT6-ligand-2
  • HY-162638
    GSK-3β inhibitor 18
    GSK-3β inhibitor 18 (compound 2) is a potent inhibitor of GSK-3β, with the IC50 of 0.0021 μM.
    GSK-3β inhibitor 18
  • HY-162639
    α-Glucosidase-IN-68 1624628-01-8
    α-Glucosidase-IN-68 (Compound 2) is an inhibitor for α-Glucosidase, AChE, and BChE, with IC50 of 0.251, 0.774 and 0.793 μM, respectively. α-Glucosidase-IN-68 exhibits antioxidant efficacy, with IC50 of 0.69 μM and 0.02 μM, in DPPH and ABTS experiments. α-Glucosidase-IN-68 exhibits antidiabetic effect in Streptozotocin (HY-13753)-induced diabetic rat models.
    α-Glucosidase-IN-68
  • HY-162652
    HSR-IN-1
    HSR-IN-1 (Compound 28) is an effective hSR (human serine racemase) inhibitor. In the presence of the cofactor Pyridoxal 5'-phosphate monohydrate (HY-W011727A), HSR-IN-1 has a Kd value of 5.4 μM and an IC50 of 18.3 μM for hSR, while the IC50 of HSR-IN-1 alone is 4.7 μM. HSR-IN-1 can be used for research on central nervous system diseases.
    HSR-IN-1
  • HY-162660
    BI-9508
    BI-9508 is a selective and cross the blood-brain barrier GPR88 agonist. BI-9508 has the potential for the research of neurological disorders.
    BI-9508
  • HY-162662
    VU6008677 2170550-99-7
    VU6008677 is a positive allosteric modulator (PAM) for M4, with EC50 of 120 nM for hM4. VU6008677 inhibits cytochrome P450, exhibits good pharmacokinetic characteristics in rats.
    VU6008677
  • HY-162669
    Mu opioid receptor antagonist 8 3040171-60-3
    Mu opioid receptor antagonist 8 (368) is a μ-opioid receptor antagonist. Mu opioid receptor antagonist 8 (368) significantly inhibits met-enkephalin-induced µOR activation of Gi.
    Mu opioid receptor antagonist 8
  • HY-162671
    BuChE-IN-12 1363947-94-7
    BuChE-IN-12 is a selective BuChE inhibitor (IC50=0.52 µM) that acts via affecting CAS and PAS sites and has potential effects against oxidative stress. BuChE-IN-12 can be used in the study of Alzheimer's disease.
    BuChE-IN-12
  • HY-162678
    HDAC-IN-75
    HDAC-IN-75 (5d) is a HDAC inhibitor, with IC50 values of 6.32 nM and 1352 nM for HDAC6 and HDAC1, respectively. HDAC-IN-75 (5d) promotes vision rescue in the atp6v0e1–/– zebrafish model of photoreceptor dysfunction.
    HDAC-IN-75
  • HY-162681
    eeAChE-IN-3
    eeAChE-IN-3 (compound YS3g) is an orally active, potent EeAChE and IL-6 inhibitor with IC50s of 0.54 μM, 0.49 μM, 8.54 μM and 0.57 μM for EeAChE, RatAChE, RatBuChE and IL-6, respectively. eeAChE-IN-3 improves STZ (HY-13753) (Streptozotocin; HY-13753)-induced learning and memory impairment in mice. eeAChE-IN-3 has the potential for Alzheimer's disease (AD) research.
    eeAChE-IN-3
  • HY-162682
    5-HT6R antagonist 4
    5-HT6R antagonist 4 (compound 30) is a neutral antagonist of 5-HT6R, with the Ki of 1 nM.
    5-HT6R antagonist 4
  • HY-162693
    AChE-IN-68
    AChE-IN-68 (compound 2l) is a potent and selective AChE inhibitor, with an IC50 value of 0.040 μM. AChE-IN-68 has high blood-brain barrier permeability. AChE-IN-68 can be used for the research of neurodegenerative disorders, particularly Alzheimer’s disease.
    AChE-IN-68
  • HY-162694
    Ferroptosis-IN-10
    Ferroptosis-IN-10 (compound D1) is an inhibitor of ferroptosis with an IC50 value of 22 nM. Ferroptosis-IN-10 has neuroprotection activity in an oxygen-glucose deprivation/reoxygenation (OGD/R) model.
    Ferroptosis-IN-10
  • HY-162699
    LY2023-001 327031-30-1
    LY2023-001 is a potent G2019S LRRK2 inhibitor with an IC50 of 12.9 nM. LY2023-001 formed stable hydrogen bonds with Glu1948, and Ala1950 in the G2019S LRRK2 protein.
    LY2023-001
  • HY-162712
    OX-201 2460722-03-4
    OX-201 is a selective agonist for OX2R with an EC50 of 8 nM. Pathological proteins produced by neurons are released into the interstitial fluid (ISF) in a manner dependent on neuronal activity and are cleared from the brain via lymphatic pathways. The outflow of pathological proteins to the ISF is related to the arousal state of neurons. OX-201 can induce neuronal awakening and promote the release of tau into the hippocampal ISF. Although OX-201 does not alter hippocampal tau levels, it has potential applications for Alzheimer's disease (AD) associated with sleep/wake rhythm disturbances.
    OX-201
  • HY-162728
    RO-76
    RO-76 is a mu opioid receptor (μOR) selective partial agonist. RO-76 binds to μOR-G-protein complex with an EC50 value of 454 nM. RO-76 reduces β-Arrestin-1/2 recruitment. RO-76 shows antinociception activity.
    RO-76
  • HY-162750
    ZJCK-6-46
    ZJCK-6-46 (32) is a potential and orally activeDYRK1A inhibitor (IC50 = 0.68 nM) with high BBB permeability (CNS+). ZJCK-6-46 (32) reduces tau phosphorylation. ZJCK-6-46 (32) ameliorates cognitive dysfunction by obviously reducing the expression of phosphorylated tau and neuronal loss in vivo.
    ZJCK-6-46
  • HY-162756
    CK1-IN-4
    CK1-IN-4 (Compound 59) is an inhibitor for casein kinase CK1δ with IC50 of 2.74 μM. CK1-IN-4 exhibits neuroprotective effect in Ethacrynic acid (HY-B1640)-treated SH-SY5Y cells.
    CK1-IN-4
Cat. No. Product Name / Synonyms Application Reactivity